The DOI matches its Crossref record; 70 of the 70 references it cites were found in a registry or an index.
m 6 A RNA methyltransferases METTL3/14 regulate immune responses to anti‐PD‐1 therapy
Open accessAbstract
An impressive clinical success has been observed in treating a variety of cancers using immunotherapy with programmed cell death‐1 (PD‐1) checkpoint blockade. However, limited response in most patients treated with anti‐PD‐1 antibodies remains a challenge, requiring better understanding of molecular mechanisms limiting immunotherapy. In colorectal cancer (CRC) resistant to immunotherapy, mismatch‐repair‐proficient or microsatellite instability‐low (pMMR‐MSI‐L) tumors have low mutation burden and constitute ~85% of patients. Here, we show that inhibition of N 6 ‐methyladenosine (m 6 A) mRNA modification by depletion of methyltransferases, Mettl3 and Mettl14, enhanced response to anti‐PD‐1 treatment in pMMR‐MSI‐L CRC and melanoma. Mettl3‐ or Mettl14‐deficient tumors increased cytotoxic tumor‐infiltrating CD8 + T cells and elevated secretion of IFN‐γ, Cxcl9, and Cxcl10 in tumor microenvironment in vivo . Mechanistically, Mettl3 or Mettl14 loss promoted IFN‐γ‐Stat1‐Irf1 signaling through stabilizing the Stat1 and Irf1 mRNA via Ythdf2. Finally, we found a negative correlation between METTL3 or METTL14 and STAT1 in 59 patients with pMMR‐MSI‐L CRC tumors. Altogether, our findings uncover a new awareness of the function of RNA methylation in adaptive immunity and provide METTL3 and METTL14 as potential therapeutic targets in anticancer immunotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660 · cited 1×
“…practice of ICIs for tumors with high mutation burden, such as non-small cell lung cancer (NSCLC) and melanoma, while the failure of response or elapse in low-mutation-burden cancer patients treated with ICIs remains common (Alexandrov et al , 2013; Sharma et al , 2017; Ganesh et al , 2019).”
Cancer immunotherapy using checkpoint blockade
Ribas, A., & Wolchok, J. D. (2018) · Science · doi:10.1126/science.aar4060 · Cited by 6,791
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645
Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
Schreiber, R. D., Old, L. J., & Smyth, M. J. (2011) · Science · doi:10.1126/science.1203486 · Cited by 6,474 · cited 1×
“…recognition of the major histocompatibility complex (MHC) complex-peptides presented on target cells, e.g., tumor cell, and T cell receptors (TCR) on immune cells (Schreiber et al , 2011; Khalil et al , 2016), whereas this recognition alone is not sufficient for initiation of the immune response.”
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Sharma, P., Hu-Lieskovan, S., Wargo, J. A., & Ribas, A. (2017) · Cell · doi:10.1016/j.cell.2017.01.017 · Cited by 5,588
Cancer immunoediting: from immunosurveillance to tumor escape
Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J., & Schreiber, R. D. (2002) · Nature Immunology · doi:10.1038/ni1102-991 · Cited by 5,393
Topology of the human and mouse m6A RNA methylomes revealed by m6A-seq
Dominissini, D., Moshitch-Moshkovitz, S., Schwartz, S., Salmon-Divon, M., Ungar, L., Osenberg, S., Cesarkas, K., Jacob-Hirsch, J., Amariglio, N., Kupiec, M., et al. (2012) · Nature · doi:10.1038/nature11112 · Cited by 4,884
The future of immune checkpoint therapy
Sharma, P., & Allison, J. P. (2015) · Science · doi:10.1126/science.aaa8172 · Cited by 4,878
N6-methyladenosine-dependent regulation of messenger RNA stability
Wang, X., Lu, Z., Gomez, A., Hon, G. C., Yue, Y., Han, D., Fu, Y., Parisien, M., Dai, Q., Jia, G., et al. (2014) · Nature · doi:10.1038/nature12730 · Cited by 4,558
Comprehensive Analysis of mRNA Methylation Reveals Enrichment in 3′ UTRs and near Stop Codons
Meyer, K. D., Saletore, Y., Zumbo, P., Elemento, O., Mason, C. E., & Jaffrey, S. R. (2012) · Cell · doi:10.1016/j.cell.2012.05.003 · Cited by 4,223
N6-Methyladenosine in nuclear RNA is a major substrate of the obesity-associated FTO
Jia, G., Fu, Y., Zhao, X., Dai, Q., Zheng, G., Yang, Y., Yi, C., Lindahl, T., Pan, T., Yang, Y.-G., et al. (2011) · Nature Chemical Biology · doi:10.1038/nchembio.687 · Cited by 4,106 · cited 8×
“(a) Changes in m 6 A mRNA levels by knockdown of either METTL14 or ALKBH5 inhibited cancer growth and invasion (Panneerdoss et al , 2018).”
InfluentialTumor mutational load predicts survival after immunotherapy across multiple cancer types
Samstein, R. M., Lee, C.-H., Shoushtari, A. N., Hellmann, M. D., Shen, R., Janjigian, Y. Y., Barron, D. A., Zehir, A., Jordan, E. J., Omuro, A., et al. (2019) · Nature Genetics · doi:10.1038/s41588-018-0312-8 · Cited by 4,071
IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
Ayers, M., Lunceford, J., Nebozhyn, M., Murphy, E., Loboda, A., Kaufman, D. R., Albright, A., Cheng, J. D., Kang, S. P., Shankaran, V., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci91190 · Cited by 3,788
ALKBH5 Is a Mammalian RNA Demethylase that Impacts RNA Metabolism and Mouse Fertility
Zheng, G., Dahl, J. A., Niu, Y., Fedorcsak, P., Huang, C.-M., Li, C. J., Vågbø, C. B., Shi, Y., Wang, W.-L., Song, S.-H., et al. (2013) · Molecular Cell · doi:10.1016/j.molcel.2012.10.015 · Cited by 3,550
N6-methyladenosine Modulates Messenger RNA Translation Efficiency
Wang, X., Zhao, B. S., Roundtree, I. A., Lu, Z., Han, D., Ma, H., Weng, X., Chen, K., Shi, H., & He, C. (2015) · Cell · doi:10.1016/j.cell.2015.05.014 · Cited by 3,483 · cited 1×
“Dynamics of RNA methylation influences a broad range of physiological processes including RNA metabolism and protein translation mainly through the readout of YTH family m 6 A binding proteins (Wang et al , 2014, 2015; Xiao et al , 2016; Hsu et al , 2017; Li et al , 2017; Nachtergaele & He, 2018).”
A METTL3–METTL14 complex mediates mammalian nuclear RNA N6-adenosine methylation
Liu, J., Yue, Y., Han, D., Wang, X., Fu, Y., Zhang, L., Jia, G., Yu, M., Lu, Z., Deng, X., et al. (2014) · Nature Chemical Biology · doi:10.1038/nchembio.1432 · Cited by 3,433
Fundamental Mechanisms of Immune Checkpoint Blockade Therapy
Wei, S. C., Duffy, C. R., & Allison, J. P. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0367 · Cited by 3,088
Mammalian WTAP is a regulatory subunit of the RNA N6-methyladenosine methyltransferase
Ping, X.-L., Sun, B.-F., Wang, L., Xiao, W., Yang, X., Wang, W.-J., Adhikari, S., Shi, Y., Lv, Y., Chen, Y.-S., et al. (2014) · Cell Research · doi:10.1038/cr.2014.3 · Cited by 2,375
Self-citationNuclear m6A Reader YTHDC1 Regulates mRNA Splicing
Xiao, W., Adhikari, S., Dahal, U., Chen, Y.-S., Hao, Y.-J., Sun, B.-F., Sun, H.-Y., Li, A., Ping, X.-L., Lai, W.-Y., et al. (2016) · Molecular Cell · doi:10.1016/j.molcel.2016.01.012 · Cited by 2,054
Immunotherapy in colorectal cancer: Rationale, challenges and potential
Ganesh, K., Stadler, Z. K., Cercek, A., Mendelsohn, R. B., Shia, J., Segal, N. H., & Diaz, L. A. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0126-x · Cited by 1,954
Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression
Garcia-Diaz, A., Shin, D. S., Moreno, B. H., Saco, J., Escuin-Ordinas, H., Rodriguez, G. A., Zaretsky, J. M., Sun, L., Hugo, W., Wang, X., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.04.031 · Cited by 1,942
CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation - a target for novel cancer therapy
Tokunaga, R., Zhang, W., Naseem, M., Puccini, A., Berger, M. D., Soni, S., McSkane, M., Baba, H., & Lenz, H.-J. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.11.007 · Cited by 1,627
Llosa, N. J., Cruise, M., Tam, A., Wicks, E. C., Hechenbleikner, E. M., Taube, J. M., Blosser, R. L., Fan, H., Wang, H., Luber, B. S., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0863 · Cited by 1,487
Type I Inteferon Gene Induction by the Interferon Regulatory Factor Family of Transcription Factors
Honda, K., Takaoka, A., & Taniguchi, T. (2006) · Immunity · doi:10.1016/j.immuni.2006.08.009 · Cited by 1,393
Mechanisms of resistance to immune checkpoint inhibitors
Jenkins, R. W., Barbie, D. A., & Flaherty, K. T. (2018) · British Journal of Cancer · doi:10.1038/bjc.2017.434 · Cited by 1,383 · cited 1×
“Among these negative regulatory pathways, PD-1 (programmed cell death – 1) and CTLA-4 (cytotoxic T-lymphocyte protein 4) have been targeted by immune checkpoint inhibitors (ICIs) to enhance tumor cell killing by T cells in immunotherapy (Jenkins et al , 2018).”
Chen, M., Wei, L., Law, C., Tsang, F. H., Shen, J., Cheng, C. L., Tsang, L., Ho, D. W., Chiu, D. K., Lee, J. M., et al. (2018) · Hepatology · doi:10.1002/hep.29683 · Cited by 1,376
m6A RNA Methylation Regulates the Self-Renewal and Tumorigenesis of Glioblastoma Stem Cells
Cui, Q., Shi, H., Ye, P., Li, L., Qu, Q., Sun, G., Sun, G., Lu, Z., Huang, Y., Yang, C.-G., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.02.059 · Cited by 1,252
Vu, L. P., Pickering, B. F., Cheng, Y., Zaccara, S., Nguyen, D., Minuesa, G., Chou, T., Chow, A., Saletore, Y., MacKay, M., et al. (2017) · Nature Medicine · doi:10.1038/nm.4416 · Cited by 1,237
Interferon-Gamma at the Crossroads of Tumor Immune Surveillance or Evasion
Castro, F., Cardoso, A. P., Gonçalves, R. M., Serre, K., & Oliveira, M. J. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00847 · Cited by 1,224
Rethinking m6A Readers, Writers, and Erasers
Meyer, K. D., & Jaffrey, S. R. (2017) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev-cellbio-100616-060758 · Cited by 1,150
In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target
Manguso, R. T., Pope, H. W., Zimmer, M. D., Brown, F. D., Yates, K. B., Miller, B. C., Collins, N. B., Bi, K., LaFleur, M. W., Juneja, V. R., et al. (2017) · Nature · doi:10.1038/nature23270 · Cited by 1,147 · cited 8×
“Our results showed that enhanced response to immunotherapy caused by depletion of Mettl3 or Mettl14 was completely abolished in both CT26 and B16 tumors (Fig 2D and E), indicating that CD8 + T cells are essential for controlling tumor growth (Ribas & Wolchok, 2018).”
InfluentialTumor Rejection After Direct Costimulation of CD8 + T Cells by B7-Transfected Melanoma Cells
Townsend, S. E., & Allison, J. P. (1993) · Science · doi:10.1126/science.7678351 · Cited by 1,136
Promoter-bound METTL3 maintains myeloid leukaemia by m6A-dependent translation control
Barbieri, I., Tzelepis, K., Pandolfini, L., Shi, J., Millán-Zambrano, G., Robson, S. C., Aspris, D., Migliori, V., Bannister, A. J., Han, N., et al. (2017) · Nature · doi:10.1038/nature24678 · Cited by 1,086
Ythdc2 is an N6-methyladenosine binding protein that regulates mammalian spermatogenesis
Hsu, P. J., Zhu, Y., Ma, H., Guo, Y., Shi, X., Liu, Y., Qi, M., Lu, Z., Shi, H., Wang, J., et al. (2017) · Cell Research · doi:10.1038/cr.2017.99 · Cited by 1,005
Weng, H., Huang, H., Wu, H., Qin, X., Zhao, B. S., Dong, L., Shi, H., Skibbe, J., Shen, C., Hu, C., et al. (2018) · Cell Stem Cell · doi:10.1016/j.stem.2017.11.016 · Cited by 968
Anti-tumour immunity controlled through mRNA m6A methylation and YTHDF1 in dendritic cells
Han, D., Liu, J., Chen, C., Dong, L., Liu, Y., Chang, R., Huang, X., Liu, Y., Wang, J., Dougherty, U., et al. (2019) · Nature · doi:10.1038/s41586-019-0916-x · Cited by 955
The future of cancer treatment: immunomodulation, CARs and combination immunotherapy
Khalil, D. N., Smith, E. L., Brentjens, R. J., & Wolchok, J. D. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.25 · Cited by 929
RNA N6-methyladenosine methylation in post-transcriptional gene expression regulation
Yue, Y., Liu, J., & He, C. (2015) · Genes & Development · doi:10.1101/gad.262766.115 · Cited by 922
Ma, J., Yang, F., Zhou, C., Liu, F., Yuan, J., Wang, F., Wang, T., Xu, Q., Zhou, W., & Sun, S. (2017) · Hepatology · doi:10.1002/hep.28885 · Cited by 912
Self-citationRNA N6-methyladenosine modification in cancers: current status and perspectives
Deng, X., Su, R., Weng, H., Huang, H., Li, Z., & Chen, J. (2018) · Cell Research · doi:10.1038/s41422-018-0034-6 · Cited by 845
Cytoplasmic m6A reader YTHDF3 promotes mRNA translation
Li, A., Chen, Y.-S., Ping, X.-L., Yang, X., Xiao, W., Yang, Y., Sun, H.-Y., Zhu, Q., Baidya, P., Wang, X., et al. (2017) · Cell Research · doi:10.1038/cr.2017.10 · Cited by 764
m6A mRNA demethylase FTO regulates melanoma tumorigenicity and response to anti-PD-1 blockade
Yang, S., Wei, J., Cui, Y.-H., Park, G., Shah, P., Deng, Y., Aplin, A. E., Lu, Z., Hwang, S., He, C., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-10669-0 · Cited by 743
Kim, K., Skora, A. D., Li, Z., Liu, Q., Tam, A. J., Blosser, R. L., Diaz, L. A., Papadopoulos, N., Kinzler, K. W., Vogelstein, B., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1410626111 · Cited by 676
Li, N., Kang, Y., Wang, L., Huff, S., Tang, R., Hui, H., Agrawal, K., Gonzalez, G. M., Wang, Y., Patel, S. P., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1918986117 · Cited by 576
Self-citationMandal, R., Samstein, R. M., Lee, K.-W., Havel, J. J., Wang, H., Krishna, C., Sabio, E. Y., Makarov, V., Kuo, F., Blecua, P., et al. (2019) · Science · doi:10.1126/science.aau0447 · Cited by 557
Regulation of the expression of inducible nitric oxide synthase
Pautz, A., Art, J., Hahn, S., Nowag, S., Voss, C., & Kleinert, H. (2010) · Nitric Oxide · doi:10.1016/j.niox.2010.04.007 · Cited by 549
Mettl3-mediated mRNA m6A methylation promotes dendritic cell activation
Wang, H., Hu, X., Huang, M., Liu, J., Gu, Y., Ma, L., Zhou, Q., & Cao, X. (2019) · Nature Communications · doi:10.1038/s41467-019-09903-6 · Cited by 503
Dynamics of the human and viral m6A RNA methylomes during HIV-1 infection of T cells
Lichinchi, G., Gao, S., Saletore, Y., Gonzalez, G. M., Bansal, V., Wang, Y., Mason, C. E., & Rana, T. M. (2016) · Nature Microbiology · doi:10.1038/nmicrobiol.2016.11 · Cited by 454
Self-citationDynamics of Human and Viral RNA Methylation during Zika Virus Infection
Lichinchi, G., Zhao, B. S., Wu, Y., Lu, Z., Qin, Y., He, C., & Rana, T. M. (2016) · Cell Host & Microbe · doi:10.1016/j.chom.2016.10.002 · Cited by 405
Self-citationThe m 6 A Reader ECT2 Controls Trichome Morphology by Affecting mRNA Stability in Arabidopsis
Wei, L.-H., Song, P., Wang, Y., Lu, Z., Tang, Q., Yu, Q., Xiao, Y., Zhang, X., Duan, H.-C., & Jia, G. (2018) · The Plant Cell · doi:10.1105/tpc.17.00934 · Cited by 391
Cross-talk among writers, readers, and erasers of m 6 A regulates cancer growth and progression
Panneerdoss, S., Eedunuri, V. K., Yadav, P., Timilsina, S., Rajamanickam, S., Viswanadhapalli, S., Abdelfattah, N., Onyeagucha, B. C., Cui, X., Lai, Z., et al. (2018) · Science Advances · doi:10.1126/sciadv.aar8263 · Cited by 339
Complex roles of Stat1 in regulating gene expression
Ramana, C. V., Chatterjee-Kishore, M., Nguyen, H., & Stark, G. R. (2000) · Oncogene · doi:10.1038/sj.onc.1203525 · Cited by 336
Regulation of Gene Expression by N-methyladenosine in Cancer
Liu, J., Harada, B. T., & He, C. (2019) · Trends in Cell Biology · doi:10.1016/j.tcb.2019.02.008 · Cited by 255
Kowanetz, M., Zou, W., Gettinger, S. N., Koeppen, H., Kockx, M., Schmid, P., Kadel, E. E., Wistuba, I., Chaft, J., Rizvi, N. A., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1802166115 · Cited by 235
Chemical Modifications in the Life of an mRNA Transcript
Nachtergaele, S., & He, C. (2018) · Annual Review of Genetics · doi:10.1146/annurev-genet-120417-031522 · Cited by 226
Atlas of quantitative single-base-resolution N6-methyl-adenine methylomes
Koh, C. W. Q., Goh, Y. T., & Goh, W. S. S. (2019) · Nature Communications · doi:10.1038/s41467-019-13561-z · Cited by 209
Lin, Y., Zhang, H., Liang, J., Li, K., Zhu, W., Fu, L., Wang, F., Zheng, X., Shi, H., Wu, S., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1408759111 · Cited by 165
Interleukin-4 mediates CDS induction on human CD4+ T-cell clones
Paliard, X., de Waal Malefijt, R., de Vries, J. E., & Spits, H. (1988) · Nature · doi:10.1038/335642a0 · Cited by 158
Gorbachev, A. V., Kobayashi, H., Kudo, D., Tannenbaum, C. S., Finke, J. H., Shu, S., Farber, J. M., & Fairchild, R. L. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.4.2278 · Cited by 126
Lichterfeld, M. D., Yu, X. G., Waring, M. T., Mui, S. K., Johnston, M. N., Cohen, D., Addo, M. M., Zaunders, J., Alter, G., Pae, E., et al. (2004) · Blood · doi:10.1182/blood-2003-12-4341 · Cited by 125
Approaches to Determine Expression of Inflammatory Cytokines
Amsen, D., de Visser, K. E., & Town, T. (2009) · Methods in molecular biology · doi:10.1007/978-1-59745-447-6_5 · Cited by 122
NUPR1 maintains autolysosomal efflux by activatingSNAP25transcription in cancer cells
Mu, Y., Yan, X., Li, D., Zhao, D., Wang, L., Wang, X., Gao, D., Yang, J., Zhang, H., Li, Y., et al. (2017) · Autophagy · doi:10.1080/15548627.2017.1338556 · Cited by 114
Self-citationEmerging links between m6A and misregulated mRNA methylation in cancer
Jaffrey, S. R., & Kharas, M. G. (2017) · Genome Medicine · doi:10.1186/s13073-016-0395-8 · Cited by 108
Immune Cells in Colorectal Cancer: Prognostic Relevance and Role of MSI
Deschoolmeester, V., Baay, M. F. D., Lardon, F., Pauwels, P., & Peeters, M. (2011) · Cancer Microenvironment · doi:10.1007/s12307-011-0068-5 · Cited by 102
Sridharan, V., Margalit, D. N., Lynch, S. A., Severgnini, M., Zhou, J. M., Chau, N. G., Rabinowits, G., Lorch, J. H., Hammerman, P. S., Hodi, F. S., et al. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.166 · Cited by 92
Veinalde, R., Grossardt, C., Hartmann, L., Bourgeois‐Daigneault, M., Bell, J. C., Jäger, D., Kalle, C. V., Ungerechts, G., & Engeland, C. E. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1285992 · Cited by 88
Association of N6-methyladenosine with viruses and related diseases
Wu, F., Cheng, W., Zhao, F., Tang, M., Diao, Y., & Xu, R. (2019) · Virology Journal · doi:10.1186/s12985-019-1236-3 · Cited by 67
IRF1 supports DNA binding of STAT1 by promoting its phosphorylation
Zenke, K., Muroi, M., & Tanamoto, K. (2018) · Immunology and Cell Biology · doi:10.1111/imcb.12185 · Cited by 57
High IFN-γ Production of Individual CD8 T Lymphocytes Is Controlled by CD152 (CTLA-4)
Pandiyan, P., Hegel, J. K., Krueger, M., Quandt, D., & Brunner-Weinzierl, M. C. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.4.2132 · Cited by 44
Profiling of N6-Methyladenosine in Zika Virus RNA and Host Cellular mRNA
Lichinchi, G., & Rana, T. M. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-8808-2_16 · Cited by 12
Self-citation
Cited by
The role of m6A RNA methylation in cancer metabolism
An, Y., & Duan, H. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01500-4 · Cited by 871
Regulatory mechanisms of PD-1/PD-L1 in cancers
Lin, X., Kang, K., Chen, P., Zeng, Z., Li, G., Xiong, W., Yi, M., & Xiang, B. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02023-w · Cited by 784
Wan, W., Ao, X., Chen, Q., Yu, Y., Ao, L., Xing, W., Guo, W., Wu, X., Pu, C., Hu, X., et al. (2022) · Molecular Cancer · doi:10.1186/s12943-021-01447-y · Cited by 457
RNA modifications: importance in immune cell biology and related diseases
Cui, L., Ma, R., Cai, J., Guo, C., Chen, Z., Yao, L., Wang, Y., Fan, R., Wang, X., & Shi, Y. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01175-9 · Cited by 405
Epigenetic regulation in the tumor microenvironment: molecular mechanisms and therapeutic targets
Yang, J., Xu, J., Wang, W., Zhang, B., Yu, X., & Shi, S. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01480-x · Cited by 388
Metadata
- Authors
- Wang, L., Hui, H., Agrawal, K., Kang, Y., Li, N., Tang, R., Yuan, J., & Rana, T. M.
- Venue
- The EMBO Journal
- Published
- 2020-09-23
- Volume
- 39
- Issue
- 20
- Pages
- e104514-e104514
- ISSN
- 0261-4189 (ISSN-L)
- 1460-2075
- OpenAlex
- W3088329595
- Cited by
- 407
- References
- 70
- FWCI
- 16.18
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.